GlobeNewswire Inc | Oct 27, 2021 07:00AM EDT

October 27, 2021

NEW HAVEN, Conn., Oct. 27, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third quarter 2021 financial results on Wednesday, November 10, 2021 before the open of the U.S. financial markets. BioXcel Therapeutics management team will also host a conference call and webcast at 8:30 AM ET to discuss the Companys financial results and to provide a general business update.

Conference Call & Webcast DetailsDate/Time: Wednesday, November 10, 2021 at 8:30 AM Eastern TimeDomestic: 877-407-5795International: 201-689-8722

The webcast and the accompanying materials will be accessible* under "News/Events" on the Investors & Media page of the Company's website atwww.bioxceltherapeutics.com.

ReplayDomestic: 877-660-6853International: 201-612-7415Conference ID: 13724785

*Replay available through at least December 11, 2021.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcels drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcels two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation associated with psychiatric and neurological disorders, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.

Contact Information

Corporate

BioXcel TherapeuticsErik Kopp1.203.494.7062ekopp@bioxceltherapeutics.com

Investor Relations

FTI ConsultingMatt Ventimiglia1.212.850.5624matthew.ventimiglia@fticonsulting.com

Media

FTI Consulting Helen OGorman1.718.408.0800helen.ogorman@fticonsulting.com

Source: BioXcel Therapeutics, Inc.